We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

100 hedge funds and large institutions have $218M invested in Cymabay Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more call options, than puts

Call options by funds: $865K | Put options by funds: $520K

17% more capital invested

Capital invested by funds: $186M → $218M (+$32M)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

6% less funds holding

Funds holding: 106 → 100 (-6)

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

40% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 30

Holders
100
Holders Change
-6
Holders Change %
-5.66%
% of All Funds
1.72%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
12
Increased
18
Reduced
30
Closed
18
Calls
$865K
Puts
$520K
Net Calls
+$345K
Net Calls Change
-$111K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$2.87M
2
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
+$2.14M
3
EI
EAM Investors
California
+$1.22M
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$834K
5
Walleye Capital
Walleye Capital
New York
+$790K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$5.32M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.03M
3
LCM
Lynx1 Capital Management
Puerto Rico
-$948K
4
Morgan Stanley
Morgan Stanley
New York
-$883K
5
PCM
Pinz Capital Management
New York
-$683K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$1.73M +$144K +39,973 +9%
Renaissance Technologies
27
Renaissance Technologies
New York
$1.72M -$85.6K -23,820 -5%
HS
28
HighVista Strategies
Massachusetts
$1.38M – – –
Two Sigma Advisers
29
Two Sigma Advisers
New York
$1.33M +$834K +232,300 +157%
EI
30
EAM Investors
California
$1.19M +$1.22M +339,778 New
State Street
31
State Street
Massachusetts
$1.18M -$85.7K -23,847 -7%
Two Sigma Investments
32
Two Sigma Investments
New York
$1.05M +$671K +186,837 +165%
E
33
Ergoteles
New York
$995K -$453K -126,240 -31%
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$928K +$428K +119,149 +82%
FI
35
Fosun International
China
$923K – – –
Goldman Sachs
36
Goldman Sachs
New York
$822K -$73K -20,321 -8%
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$786K -$146K -40,728 -15%
Walleye Capital
38
Walleye Capital
New York
$770K +$790K +219,991 New
Morgan Stanley
39
Morgan Stanley
New York
$763K -$883K -245,749 -53%
Rockefeller Capital Management
40
Rockefeller Capital Management
New York
$749K – – –
LPC
41
Lion Point Capital
New York
$704K +$788K +219,425 New
T. Rowe Price Associates
42
T. Rowe Price Associates
Maryland
$613K +$190K +52,900 +43%
Invesco
43
Invesco
Georgia
$590K -$203K -56,560 -25%
CSS
44
Cubist Systematic Strategies
Connecticut
$582K +$413K +114,911 +224%
Northern Trust
45
Northern Trust
Illinois
$492K +$5.46K +1,520 +1%
CAM
46
ClariVest Asset Management
California
$465K – – –
A
47
Abingworth
United Kingdom
$457K – – –
Deutsche Bank
48
Deutsche Bank
Germany
$445K – – –
Citigroup
49
Citigroup
New York
$389K -$544K -151,321 -58%
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$389K +$400K +111,284 New
1
2
3 4 5

CBAY Hedge Fund Activity: Q3 2022 in Review

100 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2022, worth a combined $218M — up 17% from $186M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CBAY and 12 opened new positions — a net loss of 6 holders — while 30 trimmed existing stakes and 18 added.

The largest buyer was Great Point Partners, opening a new position worth an estimated $2.87M. The largest seller was Millennium Management, cutting an estimated $5.32M.

  • 100 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2022, down from 106 in Q2 2022.
  • Funds reported $218M of Cymabay Therapeutics stock for Q3 2022, up 17% quarter-over-quarter.
  • 12 funds opened new Cymabay Therapeutics positions in Q3 2022 and 18 closed out, a net change of -6 holders.
  • The largest Cymabay Therapeutics buyer in Q3 2022 was Great Point Partners, an estimated $2.87M added.
  • The largest Cymabay Therapeutics seller in Q3 2022 was Millennium Management, an estimated $5.32M sold.

Based on aggregated 13F filings for Q3 2022.